John Simes

15.7k total citations · 5 hit papers
172 papers, 9.1k citations indexed

About

John Simes is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, John Simes has authored 172 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Oncology, 61 papers in Pulmonary and Respiratory Medicine and 40 papers in Surgery. Recurrent topics in John Simes's work include Colorectal Cancer Treatments and Studies (36 papers), Gastric Cancer Management and Outcomes (31 papers) and Glioma Diagnosis and Treatment (23 papers). John Simes is often cited by papers focused on Colorectal Cancer Treatments and Studies (36 papers), Gastric Cancer Management and Outcomes (31 papers) and Glioma Diagnosis and Treatment (23 papers). John Simes collaborates with scholars based in Australia, New Zealand and Canada. John Simes's co-authors include Val Gebski, John Zalcberg, B. Mark Smithers, Kerwyn Foo, Bryan Burmeister, Davina Ghersi, Andrew Tonkin, Wendy Hague, Kate Wilson and Andrew R. L. Stevenson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

John Simes

168 papers receiving 8.8k citations

Hit Papers

Systematic Review of the Empirical Evidence of Study Publ... 2007 2026 2013 2019 2008 2007 2015 2010 2018 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
    2008 1.1k citations Davina Ghersi, John Simes et al. profile →
  2. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis
    2007 912 citations Val Gebski, John Zalcberg et al. profile →
  3. Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer
    2015 700 citations Andrew R. L. Stevenson, Michael J. Solomon et al. profile →
  4. Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
    2010 573 citations Derek J. Jonker, Dongsheng Tu et al. profile →
  5. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
    2018 365 citations John Simes, Andrew Tonkin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Simes Australia 41 3.7k 2.9k 2.5k 1.4k 984 172 9.1k
Katherine S. Virgo United States 50 2.5k 0.7× 4.7k 1.6× 3.1k 1.2× 910 0.7× 1.0k 1.0× 203 10.9k
Chul Ahn United States 60 3.0k 0.8× 2.4k 0.8× 3.4k 1.3× 3.6k 2.7× 584 0.6× 470 14.3k
Elena B. Elkin United States 42 2.3k 0.6× 2.7k 0.9× 3.5k 1.4× 642 0.5× 1.2k 1.2× 174 9.9k
Matthew R. Sydes United Kingdom 49 3.0k 0.8× 4.0k 1.4× 7.9k 3.1× 578 0.4× 2.0k 2.1× 234 15.2k
Nandita Mitra United States 55 2.0k 0.5× 2.0k 0.7× 2.2k 0.9× 429 0.3× 581 0.6× 302 11.2k
V.E.P.P. Lemmens Netherlands 64 5.7k 1.5× 7.4k 2.6× 3.9k 1.5× 523 0.4× 1.3k 1.3× 308 13.9k
Melinda A. Maggard United States 39 4.0k 1.1× 3.2k 1.1× 1.4k 0.5× 893 0.7× 578 0.6× 82 8.0k
Michel P. Coleman United Kingdom 61 2.0k 0.5× 6.7k 2.3× 2.2k 0.9× 300 0.2× 1.2k 1.2× 291 13.3k
Yutaka Matsuyama Japan 52 4.2k 1.1× 2.7k 0.9× 2.0k 0.8× 345 0.3× 1.7k 1.7× 257 12.2k
Linda Sharp United Kingdom 52 1.9k 0.5× 4.6k 1.6× 1.8k 0.7× 244 0.2× 682 0.7× 449 11.3k

Countries citing papers authored by John Simes

Since Specialization
Citations

This map shows the geographic impact of John Simes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Simes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Simes more than expected).

Fields of papers citing papers by John Simes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Simes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Simes. The network helps show where John Simes may publish in the future.

Co-authorship network of co-authors of John Simes

This figure shows the co-authorship network connecting the top 25 collaborators of John Simes. A scholar is included among the top collaborators of John Simes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Simes. John Simes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yip, Desmond, John Zalcberg, Jean‐Yves Blay, et al.. (2025). Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial. British Journal of Cancer. 132(10). 897–904. 1 indexed citations
2.
Dakic, Aleksandar, Jing Wu, Tingting Wang, et al.. (2024). Imputation of plasma lipid species to facilitate integration of lipidomic datasets. Nature Communications. 15(1). 1540–1540. 1 indexed citations
3.
Chen, Nan, Dongsheng Tu, Stephanie Yasmin Brule, et al.. (2023). Predictive and prognostic features of metastatic colorectal cancer arising from the transverse colon: A pooled analysis of the CCTG/AGITG CO.17 and CO.20 randomized trials.. Journal of Clinical Oncology. 41(4_suppl). 124–124. 1 indexed citations
4.
Segelov, Eva, Wei Wang, Gwo Fuang Ho, et al.. (2023). LBA29 Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial. Annals of Oncology. 34. S1269–S1269. 2 indexed citations
5.
6.
Law, C. K., Andrew R. L. Stevenson, Michael J. Solomon, et al.. (2021). Healthcare Costs of Laparoscopic versus Open Surgery for Rectal Cancer Patients in the First 12 Months: A Secondary Endpoint Analysis of the Australasian Laparoscopic Cancer of the Rectum Trial (ALaCaRT). Annals of Surgical Oncology. 29(3). 1923–1934. 6 indexed citations
7.
8.
Khasraw, Mustafa, Kerrie L. McDonald, Mark Rosenthal, et al.. (2019). A RANDOMIZED PHASE II TRIAL OF VELIPARIB (V), RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH UNMETHYLATED MGMT (uMGMT) GLIOBLASTOMA (GBM): THE VERTU STUDY. Neuro-Oncology. 21. 18–18. 1 indexed citations
9.
10.
Khasraw, Mustafa, Kerrie L. McDonald, Sonia Yip, et al.. (2018). ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer. Asia-Pacific Journal of Clinical Oncology. 14. 196–196. 1 indexed citations
11.
Field, Kathryn, Madeleine King, John Simes, et al.. (2017). Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma. Journal of Neuro-Oncology. 133(3). 623–631. 10 indexed citations
12.
13.
Askie, Lisa, Louise A. Baur, Lisa Daniels, et al.. (2010). Study protocol: The Early Prevention of Obesity in CHildren (EPOCH) Collaboration - an Individual Patient Data Prospective Meta-Analysis. BMC Public Health. 10(728). 9 indexed citations
14.
Askie, Lisa, Louise A. Baur, Karen Campbell, et al.. (2010). The Early Prevention of Obesity in CHildren (EPOCH) collaboration : an individual patient data prospective meta-analysis. QUT ePrints (Queensland University of Technology).
15.
Ghersi, Davina, Nicholas Wilcken, John Simes, & Emma Donoghue. (2003). Taxane containing regimens for metastatic breast cancer. The Cochrane Database of Systematic Reviews. CD003366–CD003366. 35 indexed citations
16.
Boersma, Eric, et al.. (2001). Acute Coronary Syndrome Patients Benefit from Platelet Glycoprotein IIb/IIIa Inhibition as Part of an Initially Medical Treatment Strategy: Results of a Meta-Analysis of Phase III Randomized Trials. Circulation. 104(17).
17.
Kirby, Adrienne, David Hunt, Michael R. West, et al.. (2001). Pravastatin reduces the high rate of atherothrombotic complications in coronary heart disease patients with intermittent claudication. Journal of the American College of Cardiology. 37(2). 1 indexed citations
18.
Aylward, Philip E., David Colquhoun, Paul Glasziou, et al.. (1995). Lowering Cholesterol Levels in Patients with Coronary Heart-Disease - the 4s Trial Showed That Lowering High Cholesterol Levels Improves Survival in Patients with Coronary Heart-Disease - Do the Benefits Extend to Those with Average Cholesterol Levels. The Medical Journal of Australia. 162(9). 455–456. 2 indexed citations
19.
Werf, Frans Van de, et al.. (1993). Comparison of clinical outcomes in the US and non-US countries participating in GUSTO. Circulation. 88. 1 indexed citations
20.
Simes, John, et al.. (1993). Mortality reduction with accelerated tissue plasminogen activator is explained by early coronary patency. Circulation. 88. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katherine S. Virgo Breakdown of academic impact, for papers by Chul Ahn Breakdown of academic impact, for papers by Elena B. Elkin Breakdown of academic impact, for papers by Matthew R. Sydes Breakdown of academic impact, for papers by Nandita Mitra Breakdown of academic impact, for papers by V.E.P.P. Lemmens Breakdown of academic impact, for papers by Melinda A. Maggard Breakdown of academic impact, for papers by Michel P. Coleman Breakdown of academic impact, for papers by Yutaka Matsuyama Breakdown of academic impact, for papers by Linda Sharp
Rankless by CCL
2026